US3277166A - Maleamic acid derviatives - Google Patents
Maleamic acid derviatives Download PDFInfo
- Publication number
- US3277166A US3277166A US171829A US17182962A US3277166A US 3277166 A US3277166 A US 3277166A US 171829 A US171829 A US 171829A US 17182962 A US17182962 A US 17182962A US 3277166 A US3277166 A US 3277166A
- Authority
- US
- United States
- Prior art keywords
- naphthyl
- maleamic acid
- acid
- mole
- maleamic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- FSQQTNAZHBEJLS-UPHRSURJSA-N maleamic acid Chemical compound NC(=O)\C=C/C(O)=O FSQQTNAZHBEJLS-UPHRSURJSA-N 0.000 title description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- 238000000034 method Methods 0.000 description 20
- -1 alkyl radical Chemical class 0.000 description 18
- 239000002253 acid Substances 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 229930182555 Penicillin Natural products 0.000 description 8
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 8
- 229940049954 penicillin Drugs 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 150000002576 ketones Chemical class 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 201000005569 Gout Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ODTJDLMNBKMVGR-UHFFFAOYSA-N 1-naphthalen-1-ylpropan-2-amine Chemical compound C1=CC=C2C(CC(N)C)=CC=CC2=C1 ODTJDLMNBKMVGR-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 238000006547 Leuckart Thiophenol synthesis reaction Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 150000001728 carbonyl compounds Chemical class 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 150000004658 ketimines Chemical class 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- YZWKKMVJZFACSU-UHFFFAOYSA-N 1-bromopentane Chemical compound CCCCCBr YZWKKMVJZFACSU-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- RTCUCQWIICFPOD-UHFFFAOYSA-N 1-naphthalen-1-ylethanamine Chemical compound C1=CC=C2C(C(N)C)=CC=CC2=C1 RTCUCQWIICFPOD-UHFFFAOYSA-N 0.000 description 1
- KLTWJOFUMZCJTQ-UHFFFAOYSA-N 1-naphthalen-1-ylhexan-1-one Chemical compound C1=CC=C2C(C(=O)CCCCC)=CC=CC2=C1 KLTWJOFUMZCJTQ-UHFFFAOYSA-N 0.000 description 1
- YVQMRLAEVOPBLX-UHFFFAOYSA-N 2-methyl-1-naphthalen-1-ylpropan-1-amine Chemical compound C1=CC=C2C(C(N)C(C)C)=CC=CC2=C1 YVQMRLAEVOPBLX-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- NMGOXQZHUXFERQ-UHFFFAOYSA-N 4-naphthalen-1-ylbutan-2-amine Chemical compound C1=CC=C2C(CCC(N)C)=CC=CC2=C1 NMGOXQZHUXFERQ-UHFFFAOYSA-N 0.000 description 1
- VEYCCHNUJNXSRR-UHFFFAOYSA-N 4-naphthalen-1-ylbutan-2-one Chemical compound C1=CC=C2C(CCC(=O)C)=CC=CC2=C1 VEYCCHNUJNXSRR-UHFFFAOYSA-N 0.000 description 1
- ZGJUXLRCZXCYTO-UHFFFAOYSA-N 4-naphthalen-2-ylbutan-2-one Chemical compound C1=CC=CC2=CC(CCC(=O)C)=CC=C21 ZGJUXLRCZXCYTO-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N N-butylamine Natural products CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000003312 cholesterol blood level Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- FNMGQNDAHZHJIZ-UHFFFAOYSA-N cyclohexyl(naphthalen-1-yl)methanone Chemical compound C=1C=CC2=CC=CC=C2C=1C(=O)C1CCCCC1 FNMGQNDAHZHJIZ-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000000738 kidney tubule Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- LWLPYZUDBNFNAH-UHFFFAOYSA-M magnesium;butane;bromide Chemical compound [Mg+2].[Br-].CCC[CH2-] LWLPYZUDBNFNAH-UHFFFAOYSA-M 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
- C07C49/788—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic with keto groups bound to a condensed ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
Definitions
- This invention comprises novel derivatives of malearnic acid and in particular those derivatives wherein a hydrogen of the amino group of nraleamic acid is replaced by a naphthyl-lower alkyl radical and more particularly by derivatives wherein the lower alkylene chain of the naphthyl-lower alkyl substituent is additionally substituted by one or more groups such as by a lower alkyl, phenyl, benzyl, and the like radicals, or is substituted by any combination of these radicals.
- R is a straight chain alkylene radical having at least one and no more than three carbon atoms in the chain connecting the naphthyl radical and the nitrogen of the amino group of maleamic acid; in other words, R is a methylene, ethylene or propylene radical, each valence of the said alkylene radicals being satisfied by one of the following: (a) hydrogen, (b) a lower alkyl radical having from 1 to 10 carbon atoms, and preferably having up to 6 carbon atoms in a straight or branchedchain or alicyclic, such as a methyl, isoor normal-propyl, isoor normal-butyl, amyl, hexyl, cyclopentyl, cyclohexyl, and the like, (c) a mononuclear aryl, preferably a phenyl radical
- the compounds of this invention posses a 'variety of properties and are especially useful because they inhibit the excretion of penicillin through the kidney tubules thus providing prolonged blood levels of penicillin. Because of this property the new compounds of this invention are useful as adjuvants for use in conjunction with the administration of penicillin to provide an increase in the blood plasma pencillin concentration with a given dose of penicillin, thereby making possible very high penicillin blood levels, or permitting the use of smaller quantities of penicillin for providing, a given blood level, or permitting less frequent administration of penicillin while maintaining a penicillin blood level adequate for bactericidal or bacteriostatic purposes.
- Some of the compounds additionally enhance the excretion of uric acid from the body and therefore are useful agents in the treatment of gout or gouty arthritis and in alleviating symptoms of these conditions and of complications associated with gout and gouty arthritis.
- naphthylalkyl-maleamic acids or their salts or simple esters can be administered in conventional dosage forms such as in a capsule, pill or tablet either with or without therapeutically inert materials and with or without other therapeutically active substances or in the form of a sterile solution and the like.
- the maleamic acid'derivatives of this invention possess one or more of the above properties to varying degrees, the compounds having a (l-naphthyl)-lower alkylene or a (2-naphthyl)-lower alkylene radical attached to the amino nitrogen of rnaleamic acid, and especially 1- or 2-naph-thylethylmaleamic acids which also have attached to the ethylene chain a lower alkyl group, and especially a methyl radical, possess one or more of the above described properties to a marked degree.
- the maleamic acid derivatives of this invention are easily prepared by bringing together a solution of the selected naphthyl-lower-alkylamine and a solution of maleic anhydride.
- the reaction between the ingredients occurs quite readily at room temperature accompanied by the precipitation of the maleamic acid derivative from the reaction mixture, which then can be separated by known conventional methods, as by filtration or evaporation of the solvent and the like.
- Ether has been found to be an effective solvent for the naphthyl-lower-alkylamine as well as for maleic anhydride, although other solvents could be used in its place.
- naphthylalkylamines used in preparing the :rnaleamic acid derivatives of this invention are new compounds which can readily be prepared by one or another of the many well-known methods for preparing naphthylalkylamines.
- a carbonyl compound is converted by means of the Leuckart reaction to the desired naphthylalkylamine. This reaction involves heating the carbonyl compound (i.e., a ketone or an aledhyde) with formamide and formic acid preferably under reflux conditions to form the formamide derivative of the desired naphthylalkylamine.
- This compound after hydrolysis with a mineral acid, such as hydrochloric acid, generally is isolated either (a) as an acid addition salt thereof, such as the hydrochloride salt, which may be insoluble in the reaction medium or (b) by treatment of the reaction medium with alkali, such as sodium hydroxide, to obtain the free base, which then is extracted with a solvent, such as ether, and purified by distillation of the base.
- a mineral acid such as hydrochloric acid
- the selected nitriles can be reacted with a Grignard reagent thus forming the corresponding ket-imine.
- the ketimine then is hydrolyzed to the corresponding carbonyl .compound and the latter product converted by means of the Leuckart reaction (supra) to the naphthylalkylamine.
- novel maleamic acid derivatives of this invention as well as their intermediate naphthylalkylamines, which contain one asymmetric carbon atom in the ethylene or propylene radical will-.be obtained as racemic mixtures which can be separated into the dextrorotatory and levorotatory isomers by known methods.
- novel maleamic acid derivatives of this invention as well as the corresponding naphthylalkylamines, which contain two asymmetric carbon atoms in the ethylene or propylene radical will be obtained as diasterioisomers.
- diasterioisomer having the higher melting point is considered to be the wisomer and that having the lower melting point is considered to be the fl-isomer.
- While greater activity may reside in one or another of the oc-isomer or fi-isomer or in the dextroor levorotatory antipode of one or another of these isomers, in general, mixtures of their racemates can be employed for one or another of the uses identified above for which the individual compound may possess the desired property.
- the acid extract is refluxed for two hours, cooled and extracted with a mixture of ether and benzene 1:1) (250 ml.). The extract is washed with sodium carbonate and saturated sodium chloride solution, dried over sodium sulfate and evaporated to dryness. The residue is distilled to give 10.4 g. of 1-(1-naphthyl)-l-hexanone, B.P. 133 C. at 0.4 mm. pressure.
- Step B Preparation of 1 -(1 -naphthyl -hexylamine.-A mixture of the ketone prepared in Step A 10.2 g., 0.045 mole), formamide (8.1 g., 0.18 mole) and a few drops of formic acid is placed in a flask equipped with a condenser set for downward distillation. The mixture is heated at l75l80 C. (internal temperature) for 14 hours. Whenever the vapors above the reaction mixture become basic, a few ml. of formic acid is added. The reaction mixture then is extracted with benzene, the henzene evaporated and the residue mixed with concentrated hydrochloric acid (10 ml.).
- Step C Preparation of N-[1-(1-naphthyl)-1-hexyl]- maleamic acid.An ether (30 ml.) solution of the amine prepared in Step B (5.68 g., 0.025 mole) is added slowly to an ether (30 ml.) solution of maleic anhydride (2.45 g., 0.025 mole). A clear solution results which gradually deposits a solid. After 16 hours, the precipitate is collected and Washed with ether. The solid is crystallized from a mixture of methanol and water to give 4.46 g. of N-[1-(1-naphthyl)-l-hexyl]-maleamic acid, M.P. 136- 137 C.
- Step A Preparation of l -(L-naplithj l)Z-methylpropylamine-By replacing theketone employed in Example 5, Step 13, by l naphthyl isopropyl ketone (10.8 g., 0.053 mole) and following substantially the same procedure described in Step B of Example 5 there is obtained 7.5 g. of 1-(l-naphthyl)-2-methylpropylamine, B.P. 112-114" C. at 0.2 mm; pressure.
- Step B Preparation of N-[1-(I-naphthyl)-2-methyl-I- propyl] analeamic acid.
- the amine (4.97 g., 0.025 mole) prepared in Step A is reacted with maleic anhydride (2.45 g., 0.025 mole) by substantially the same procedure de scribed in Example 5, Step C, to give N-[l-(l-naphthyl) 2-methyl-1-propyl]-maleamic acid which, after crystallization from a mixture of benzene and hexane, melts at 141-142 C.
- Step A Preparation of 1 -(1 -naphthyl -amylam'ine.By replacing the ketone used in Example 5, Step B, by naphthyl)-l-pentanone (10.0 g., 0.047 mole), (prepared from butyl magnesium bromide and l-naphthyl cyanide by the method described in Example 5, Step A) and following subs ant a ly the same procedure described in Example 5, Step B, there is obtained 7.1 g. of 1-( l-naphthyl) amylamine, B.P. 119123 C. at 0.1-0.2 mm. pressure.
- Step B Preparation of N-[1-(1-naphthyl)-1-amyl]- maleamic acid.-The amine (6.94 g., 0.03 mole) obtained in Step A is reacted with maleic anhydride (2.94 g., 0.03 mole) by substantially the same method described in Example 5, Step C, to give N-[1-(1-naphthyl) 1-amyl]-maleamic acid which, after crystallization from a mixture of isopropyl alcohol and water, yields 7 g. of product, M.P. 153-154 C.
- Step B Preparation of N-[a-(l-naphthyl)-hexahydr0- benzyl1-maleamic acid.
- the amine (6.0 g., 0.025 mole) obtained in Step A is reacted with maleic anhydride (2.45 g., 0.025 mole) by substantially the same method described in Example 5, Step C, to give N-[a-(1-naphthyl)- hexahydrobenzyH-maleamic acid that separates as an oil and then solidifies after standing at room temperature for several hours.
- Step B Preparation of N[] -(1-Naphthyl) -3-butyl]- maleamic acid.-Reaction of equimolecular quantities of the above amine and maleic anhydride by substantially the same procedure described in Example 5, Step C, gives N[1-(l-naphthyl)-3-butyl]-maleamic acid.
- Step A Preparation of 1-(Z-naphthyl)-3-butylamine.
- Step B By replacing the ketone used in Example 5, Step B, by an equimolecular quantity of 1-(2-naphthyl)-3butanone, and following substantially the same procedure described in 6 Example 5, Step B, there is obtained 1-(2-naphthy1)-3- butylamine.
- Step B Preparation of N-[I-(Z-naphthyl)-3-batyl]- maleamic acid.Reaction of equimolecular quantities of the above amine and maleic anhydride by substantially the same procedure described in Example 5, Step C, gives N[ l-(2-naphthyl)-3-butyl]-ma1eamic acid.
- N-(napht-hyl-R)-ma1eamic acid having the structural wherein R is an alkylene group having from 1 to 3 carbon atoms linked together in a straight chain between the naphthyl radical and the nitrogen atom of the maleamic acid residue, each remaining valence of said alkylene group being satisfied by a radical selected from the group consisting of hydrogen, lower alkyl, cyclohexy-l and phenyl.
- N-( 1-naphthyl-3 -lower alkyl) -maleamic acid N-( 1-naphthyl-3 -lower alkyl) -maleamic acid.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
United States Patent 3,277,166 MALEAMIC ACID DERIVATIVES Everett M. Schultz, Ambler, Pa., assignor to Merck & C0., Rahway, N.J., a corporation of New Jersey No Drawing. Filed Feb. 8, 1962, Ser. No. 171,829 8 Claims. (Cl. 260--518) This invention comprises novel derivatives of malearnic acid and in particular those derivatives wherein a hydrogen of the amino group of nraleamic acid is replaced by a naphthyl-lower alkyl radical and more particularly by derivatives wherein the lower alkylene chain of the naphthyl-lower alkyl substituent is additionally substituted by one or more groups such as by a lower alkyl, phenyl, benzyl, and the like radicals, or is substituted by any combination of these radicals.
The novel compounds of this invention can be illustrated 'by the following structural formula:
and includes the alkali metal salts thereof as well as simple ester derivatives, such as esters derived from the low molecular Weight alcohols. In the above structure, R is a straight chain alkylene radical having at least one and no more than three carbon atoms in the chain connecting the naphthyl radical and the nitrogen of the amino group of maleamic acid; in other words, R is a methylene, ethylene or propylene radical, each valence of the said alkylene radicals being satisfied by one of the following: (a) hydrogen, (b) a lower alkyl radical having from 1 to 10 carbon atoms, and preferably having up to 6 carbon atoms in a straight or branchedchain or alicyclic, such as a methyl, isoor normal-propyl, isoor normal-butyl, amyl, hexyl, cyclopentyl, cyclohexyl, and the like, (c) a mononuclear aryl, preferably a phenyl radical, or (d) a mononuclear aryl-lower alkyl radical such as a benzyl radical, for example.
The compounds of this invention posses a 'variety of properties and are especially useful because they inhibit the excretion of penicillin through the kidney tubules thus providing prolonged blood levels of penicillin. Because of this property the new compounds of this invention are useful as adjuvants for use in conjunction with the administration of penicillin to provide an increase in the blood plasma pencillin concentration with a given dose of penicillin, thereby making possible very high penicillin blood levels, or permitting the use of smaller quantities of penicillin for providing, a given blood level, or permitting less frequent administration of penicillin while maintaining a penicillin blood level adequate for bactericidal or bacteriostatic purposes.
Some of the compounds additionally enhance the excretion of uric acid from the body and therefore are useful agents in the treatment of gout or gouty arthritis and in alleviating symptoms of these conditions and of complications associated with gout and gouty arthritis.
Additionally,some of the compounds have been found to inhibit the biosynthesis of cholesterol in liver homogenates in vitro. They have also been found to lower the the incidence and severity of atherosclerotic plaques in the thoracic aorta. of estrogen-treated chickens which were treated with these compounds as compared with their estrogen-treated controls, and to lower the plasma level of cholesterol in rats which had been challenged with quantities of saturated fats such as lard, known to produce an increased cholesterol blood level in these animals. Accordingly, these compounds also are potentially useful in lowering blood cholesterol levels in humans which is "ice considered an important function of chemotherapeutic agents in the treatment of atherosclerosis.
The naphthylalkyl-maleamic acids or their salts or simple esters can be administered in conventional dosage forms such as in a capsule, pill or tablet either with or without therapeutically inert materials and with or without other therapeutically active substances or in the form of a sterile solution and the like.
While all of the maleamic acid'derivatives of this invention possess one or more of the above properties to varying degrees, the compounds having a (l-naphthyl)-lower alkylene or a (2-naphthyl)-lower alkylene radical attached to the amino nitrogen of rnaleamic acid, and especially 1- or 2-naph-thylethylmaleamic acids which also have attached to the ethylene chain a lower alkyl group, and especially a methyl radical, possess one or more of the above described properties to a marked degree.
The maleamic acid derivatives of this invention are easily prepared by bringing together a solution of the selected naphthyl-lower-alkylamine and a solution of maleic anhydride. The reaction between the ingredients occurs quite readily at room temperature accompanied by the precipitation of the maleamic acid derivative from the reaction mixture, which then can be separated by known conventional methods, as by filtration or evaporation of the solvent and the like. Ether has been found to be an effective solvent for the naphthyl-lower-alkylamine as well as for maleic anhydride, although other solvents could be used in its place.
Some of the naphthylalkylamines used in preparing the :rnaleamic acid derivatives of this invention are new compounds which can readily be prepared by one or another of the many well-known methods for preparing naphthylalkylamines. By one such method, a carbonyl compound is converted by means of the Leuckart reaction to the desired naphthylalkylamine. This reaction involves heating the carbonyl compound (i.e., a ketone or an aledhyde) with formamide and formic acid preferably under reflux conditions to form the formamide derivative of the desired naphthylalkylamine. This compound, after hydrolysis with a mineral acid, such as hydrochloric acid, generally is isolated either (a) as an acid addition salt thereof, such as the hydrochloride salt, which may be insoluble in the reaction medium or (b) by treatment of the reaction medium with alkali, such as sodium hydroxide, to obtain the free base, which then is extracted with a solvent, such as ether, and purified by distillation of the base.
Alternatively the selected nitriles can be reacted with a Grignard reagent thus forming the corresponding ket-imine. The ketimine then is hydrolyzed to the corresponding carbonyl .compound and the latter product converted by means of the Leuckart reaction (supra) to the naphthylalkylamine.
The above and other methods for preparing the amines and the novel maleamic acid derivatives of this invention will be described in more detail by the following examples.
The novel maleamic acid derivatives of this invention, as well as their intermediate naphthylalkylamines, which contain one asymmetric carbon atom in the ethylene or propylene radical will-.be obtained as racemic mixtures which can be separated into the dextrorotatory and levorotatory isomers by known methods.
The novel maleamic acid derivatives of this invention, as well as the corresponding naphthylalkylamines, which contain two asymmetric carbon atoms in the ethylene or propylene radical will be obtained as diasterioisomers. In this specification and in the claims the diasterioisomer having the higher melting point is considered to be the wisomer and that having the lower melting point is considered to be the fl-isomer. The u-isomer and the ,li-isomer,
of course, also will be obtained as racemic mixtures which can be separated by known methods.
While greater activity may reside in one or another of the oc-isomer or fi-isomer or in the dextroor levorotatory antipode of one or another of these isomers, in general, mixtures of their racemates can be employed for one or another of the uses identified above for which the individual compound may possess the desired property.
The preparation of the novel maleamic acid derivatives of this invention is illustrated by the following examples. It is to be understood, of course, that these examples are illustrative and not limitative of the compounds of this invention and of the methods by which they can be prepared. The examples also illustrate methods for preparing suitable dosage for-ms of the maleamic acid derivatives of this invention.
EXAMPLE 1 N [1 (1 map]: thyl -2-pr0pyl -m aleamic acid 1-(l-naphthyl)-2-propylamine (1.85 g., 0.01 mole) is dissolved in ether (20 ml.) and the solution added slowly to an ether solution (30 ml.) of maleic anhydride (0.98 g., 0.01 mole). A solid separates at once. After the reaction mixture has been kept at room temperature for 30 minutes the solid is collected and dried in air at 65 C. to give 2.6 g. of product, M.P. l48158 C. After crystallization from ethanol there is obtained 1.8 g. of N-[l- (l naphthyl) 2 propyl]-maleamic acid, M.P. 162.5- 163 C.
AnaIysis.Calculated for C H NO C, 72.06; H, 6.05; N, 4.94. Found: C, 72.08; H,,6.20; N,'4.94.
EXAMPLE 2 N -[1 -(2-nap-hthyl -1 ethyl ]-maleamic acid By replacing l-( l-naphthyl)-2-propylamine used in Example l by 1-(1-naphthyl)ethylamine (5.13 g.) and reacting it with maleic anhydride (2.94 g.) by substantially the same method described in Example 1, there is obtained N-[l-(2-naphthyl)-1-ethyl]-maleic acid which after crystallization from absolute alcohol gives 5.8 g. of product, M.P. 160-16l C.
Analysis-Calculated for C H NO C, 71.36; H, 5.61; N, 5.20. Found: C, 71.73; H, 5.64; N, 5.19.
EXAMPLE 3 N -[I -(1 -naphthyl) -1 -prpyl]-maleamic acid By replacing 1-(l-naphthyl)-2-propylamine used in Example 1 by l-(l-naphthyl)-propylamine (5.55 g., 0.03 mole) and reacting it with maleic anhydride (2.94 g., 0.03 mole) by substantially the same method described in Example 1, there is obtained N-[l-(l-naphthyl)-1-propyl]- maleamic acid which after crystallization from alcohol gives 5.3 g. of product, M.P. 170-171 C.
Analysis.Calculated for C17H17NO31 C, 72.06; H, 6.05; N, 4.94. Found: C, 72.28; H, 6.12; N, 4.94,
EXAMPLE 4 N [1 -(1 -naphthyl -1 -butyl] -maleamic acid EXAMPLE 5 N- [1-(1-naphthyl)-1-hexyl] -maleamic acid Step A: Preparation of 1 -(1 -naphtlzyl )-1-hexanone.--A Grignard reagent is prepared in ether from normal amyl bromide (33.2 g., 0.22 mole) and magnesium (5.1 g.,
0.21 g. atom). To this is added l-naphthyl cyanide (30.6 g., 0.2 mole) dissolved in dry toluene (300 ml.) The ether is removed by distillation and the residual mixture heated at the boiling point of toluene for 5 hours, cooled and added to a concentrated solution of ammonium chloride ml.). The toluene phase is separated and the aqueous phase extracted with ether. The organic layers are combined and the product, l-naphthyl amyl ketimine, extracted with 6N sulfuric acid (200 ml.). The acid extract is refluxed for two hours, cooled and extracted with a mixture of ether and benzene 1:1) (250 ml.). The extract is washed with sodium carbonate and saturated sodium chloride solution, dried over sodium sulfate and evaporated to dryness. The residue is distilled to give 10.4 g. of 1-(1-naphthyl)-l-hexanone, B.P. 133 C. at 0.4 mm. pressure.
Step B: Preparation of 1 -(1 -naphthyl -hexylamine.-A mixture of the ketone prepared in Step A 10.2 g., 0.045 mole), formamide (8.1 g., 0.18 mole) and a few drops of formic acid is placed in a flask equipped with a condenser set for downward distillation. The mixture is heated at l75l80 C. (internal temperature) for 14 hours. Whenever the vapors above the reaction mixture become basic, a few ml. of formic acid is added. The reaction mixture then is extracted with benzene, the henzene evaporated and the residue mixed with concentrated hydrochloric acid (10 ml.). The mixture is refluxed for 12 hours, cooled, diluted with water, made basic with sodium hydroxide and extracted with ether. The ether extract is dried over sodium sulfate and evaporated. The residue is distilled to give 8.2 g. of l-(l-naphthyl) hexylamine, B.P. 129142 C. at 0.3 mm. pressure.
Step C: Preparation of N-[1-(1-naphthyl)-1-hexyl]- maleamic acid.An ether (30 ml.) solution of the amine prepared in Step B (5.68 g., 0.025 mole) is added slowly to an ether (30 ml.) solution of maleic anhydride (2.45 g., 0.025 mole). A clear solution results which gradually deposits a solid. After 16 hours, the precipitate is collected and Washed with ether. The solid is crystallized from a mixture of methanol and water to give 4.46 g. of N-[1-(1-naphthyl)-l-hexyl]-maleamic acid, M.P. 136- 137 C.
Analysis.--Calculated for C H NO C, 73.82; H, 7.12; N, 4.30. Found: C, 74.03; H, 7.19; N, 4.30.
EXAMPLE 6 N- [1-(] -naphthyl) -2-methyl-1 -propyl] anaieamicyacid Step A: Preparation of l -(L-naplithj l)Z-methylpropylamine-By replacing theketone employed in Example 5, Step 13, by l naphthyl isopropyl ketone (10.8 g., 0.053 mole) and following substantially the same procedure described in Step B of Example 5 there is obtained 7.5 g. of 1-(l-naphthyl)-2-methylpropylamine, B.P. 112-114" C. at 0.2 mm; pressure.
Step B: Preparation of N-[1-(I-naphthyl)-2-methyl-I- propyl] analeamic acid.The amine (4.97 g., 0.025 mole) prepared in Step A is reacted with maleic anhydride (2.45 g., 0.025 mole) by substantially the same procedure de scribed in Example 5, Step C, to give N-[l-(l-naphthyl) 2-methyl-1-propyl]-maleamic acid which, after crystallization from a mixture of benzene and hexane, melts at 141-142 C.
Analysis.Ca1culated for C H NO C, 72.70; H, 6.44; N, 4.71. Found: C, 72.58; H, 6.55; N, 4.69.
EXAMPLE 7 N-[I-(I-naphthyl) -1-amyl] -maleamic acid Step A: Preparation of 1 -(1 -naphthyl -amylam'ine.By replacing the ketone used in Example 5, Step B, by naphthyl)-l-pentanone (10.0 g., 0.047 mole), (prepared from butyl magnesium bromide and l-naphthyl cyanide by the method described in Example 5, Step A) and following subs ant a ly the same procedure described in Example 5, Step B, there is obtained 7.1 g. of 1-( l-naphthyl) amylamine, B.P. 119123 C. at 0.1-0.2 mm. pressure.
Step B: Preparation of N-[1-(1-naphthyl)-1-amyl]- maleamic acid.-The amine (6.94 g., 0.03 mole) obtained in Step A is reacted with maleic anhydride (2.94 g., 0.03 mole) by substantially the same method described in Example 5, Step C, to give N-[1-(1-naphthyl) 1-amyl]-maleamic acid which, after crystallization from a mixture of isopropyl alcohol and water, yields 7 g. of product, M.P. 153-154 C.
Analysis.Calcu]ated for C H NO C, 73.29; H, 6.80; N, 4.50. Found: C, 73.19; H, 6.93; N, 4.48.
EXAMPLE 8 N [at-(1 -naphthyl -hexahydrobenzyl -maleam z'c acid Step A: Preparation of a-( 1 -napht hyl -hexhydr0benzylamine.By replacing the ketone used in Example 5, Step B, by cyclohexy l-naphthyl ketone (11.2 g., 0.047 mole) and reacting it with formamide (8.5 g., 0.19 mole) by substantially the same method described in Example 5, Step B, there is obtained 8.5 g. of a-(l-naphthylhexahydrobenzylamine as a viscous oil, B.P. 151-152 C. at 0.4 mm. pressure.
Step B: Preparation of N-[a-(l-naphthyl)-hexahydr0- benzyl1-maleamic acid.The amine (6.0 g., 0.025 mole) obtained in Step A is reacted with maleic anhydride (2.45 g., 0.025 mole) by substantially the same method described in Example 5, Step C, to give N-[a-(1-naphthyl)- hexahydrobenzyH-maleamic acid that separates as an oil and then solidifies after standing at room temperature for several hours.
EXAMPLE 9 N -[1 -(1 -naphthyl -phenyl-2-pr0pyl -maleamic acid EXAMPLE 10 N [1 -(1 -naphthyl) -3-butyl] -maleamic acid Step A:Preparati0n of I-(Z-naphthyl)-3-batylamine.- By replacing the ketone used in Example 5, Step B, by an equimolecular quantity of 1-(1-naphthyl)-3-butanone, and following substantially the same procedure described in Example 5, Step B, there is obtained 1-(1-naphthyl)3- butylamine.
Step B: Preparation of N[] -(1-Naphthyl) -3-butyl]- maleamic acid.-Reaction of equimolecular quantities of the above amine and maleic anhydride by substantially the same procedure described in Example 5, Step C, gives N[1-(l-naphthyl)-3-butyl]-maleamic acid.
EXAMPLE 11 N -[1 (Z-naphthyl -3-butyl] -maleamic acid Step A: Preparation of 1-(Z-naphthyl)-3-butylamine. By replacing the ketone used in Example 5, Step B, by an equimolecular quantity of 1-(2-naphthyl)-3butanone, and following substantially the same procedure described in 6 Example 5, Step B, there is obtained 1-(2-naphthy1)-3- butylamine.
Step B: Preparation of N-[I-(Z-naphthyl)-3-batyl]- maleamic acid.Reaction of equimolecular quantities of the above amine and maleic anhydride by substantially the same procedure described in Example 5, Step C, gives N[ l-(2-naphthyl)-3-butyl]-ma1eamic acid.
While the above examples describe the preparation of certain illustrative compounds falling within the scope of the generic structure, it is to be understood that the invention is not to be limited by or to these examples nor by the specific reaction conditions described for the preparation of the compounds, but is to be understood to embrace variations and modifications falling within the scope of the appended claims.
What is claimed is:
1. N-(napht-hyl-R)-ma1eamic acid having the structural wherein R is an alkylene group having from 1 to 3 carbon atoms linked together in a straight chain between the naphthyl radical and the nitrogen atom of the maleamic acid residue, each remaining valence of said alkylene group being satisfied by a radical selected from the group consisting of hydrogen, lower alkyl, cyclohexy-l and phenyl.
2. N-(naphthyl-R)-maleamic acid having the structural formula 3}RNHC OCH=CHOOOH wherein R is lower alkyl.
. N[ 1-( l-naphthyl -2-propyl] -maleamic acid.
. N-[1-( 1-naphthyl)-1-lower alky] -maleamic acid. N- 1- Z-naphthyl -1-lower alkyl] -maleamic acid. N-( l-naphthyl-Z-lower alkyl) -Inaleamic acid.
. N-( 1-naphthyl-3 -lower alkyl) -maleamic acid.
References Cited by the Examiner UNITED STATES PATENTS 3,018,292 1/1962 Sauers et al. 260518 OTHER REFERENCES Frankel et al.: J. Am. Chem. Soc. 75, 331 (1953).
LEON ZITVER, Primary Examiner.
CHARLES B. PARKER, Examiner.
G. P. DANGELO, B. HELFIN, Assistant Examiners.
Claims (1)
1. N-(NAPHTHYL-R)-MALEAMIC ACID HAVING THE STRUCTUREAL FORMULA
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US171829A US3277166A (en) | 1962-02-08 | 1962-02-08 | Maleamic acid derviatives |
| FR923926A FR1519485A (en) | 1962-02-08 | 1963-02-06 | New derivatives of maleamic acid and their production |
| FR933674A FR2584M (en) | 1962-02-08 | 1963-05-03 | New drugs consisting of derivatives of maleamic acid. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US171829A US3277166A (en) | 1962-02-08 | 1962-02-08 | Maleamic acid derviatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3277166A true US3277166A (en) | 1966-10-04 |
Family
ID=22625298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US171829A Expired - Lifetime US3277166A (en) | 1962-02-08 | 1962-02-08 | Maleamic acid derviatives |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US3277166A (en) |
| FR (2) | FR1519485A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5616803A (en) * | 1993-02-12 | 1997-04-01 | Banyu Pharmaceutical Co., Ltd. | Substituted amic acid derivatives |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3018292A (en) * | 1959-11-12 | 1962-01-23 | Union Carbide Corp | Preparation of maleimides |
-
1962
- 1962-02-08 US US171829A patent/US3277166A/en not_active Expired - Lifetime
-
1963
- 1963-02-06 FR FR923926A patent/FR1519485A/en not_active Expired
- 1963-05-03 FR FR933674A patent/FR2584M/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3018292A (en) * | 1959-11-12 | 1962-01-23 | Union Carbide Corp | Preparation of maleimides |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5616803A (en) * | 1993-02-12 | 1997-04-01 | Banyu Pharmaceutical Co., Ltd. | Substituted amic acid derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| FR1519485A (en) | 1968-04-05 |
| FR2584M (en) | 1964-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3231042B2 (en) | Nitrate ester of 2- (2,6-di-halo-phenylamino) phenylacetic acid derivative and method for producing the same | |
| CH644348A5 (en) | OXIDIZED AMINO-ETHERS, THEIR PREPARATION PROCESS AND THE MEDICAMENT CONTAINING THEM. | |
| DE3317107A1 (en) | IMMUNOMODULATING AGENT | |
| JPS63192758A (en) | 1-(4-hydroxy-3, 5-di-tert-butylbenzoyl) homopiperadine and its derivative | |
| CS267551B1 (en) | Pharmaceutical agents for asthma treatment and method of effective substance production | |
| EP0062596B1 (en) | Derivatives of 4-aminoethoxy-5-isopropyl-2-methyl phenol, process for their preparation and their use as medicines | |
| US4655973A (en) | Conjugated polyprenylcarboxylic acids and their derivatives | |
| DE69105786T2 (en) | Urea derivatives, their preparation and pharmaceutical compositions containing them. | |
| EP0239436B1 (en) | Tricyclic derivative, namely 5-(3-chloro-6-methyl-5,5-dioxo-6,11-dihydro-dibenzo[C,F] [1,2]-thiazepin-11-ylamino)-pentanoic acid, process for its preparation and medicines and medicines containing it | |
| US3277166A (en) | Maleamic acid derviatives | |
| CH642348A5 (en) | ALKYLTHIOPHENOXYALKYLAMINE. | |
| US4071686A (en) | Novel benzylidene amino-oxyalkyl carboxylic acids and carboxylic acid derivatives | |
| US3066167A (en) | 4-amino-3, 5-dichloro-benzamides | |
| US4275068A (en) | Lipid lowering alkylene glycols and ester derivatives thereof | |
| US3642869A (en) | 5 8-dihydronaphthyloxy acetic acids | |
| US3222395A (en) | Maleamic ackd derivatives | |
| US4214095A (en) | Chlorobenzyl phenoxy alkoxylates | |
| LUTZ et al. | ANTIMALARIALS. 1 AMIDES RELATED TO PHENYLPANTOTHENONE | |
| US3494953A (en) | 4,7-dihydro-3alpha-cyano-7alpha-indanecarboxylic acid and lower alkyl esters thereof | |
| DE2725245A1 (en) | METHYLAMINE DERIVATIVES, THE PROCESS FOR THEIR PRODUCTION AND THE PHARMACEUTICAL OR VETERINARY MEDICAL COMPOSITIONS THEREOF | |
| PT93675B (en) | PROCESS FOR THE PREPARATION OF DERIVATIVES OF UNATURATED AMINODYCARBOXYL ACIDS, CONTAINING PHOSPHORUS | |
| US4042584A (en) | Ethynylaryl phenyl cyclopropyl thiazines and morpholines | |
| CH495935A (en) | 2-methylenealkanoyl-phenoxy-alkanecarboxylic acids | |
| FR2475543A1 (en) | BENZYLIDENIC DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | |
| US4435591A (en) | Compound with analgesic, antiinflammatory and antipyretic activity, and pharmaceutical compositions therefrom |